Home/Pipeline/Orca-T

Orca-T

Hematologic Malignancies

Phase 3Active

Key Facts

Indication

Hematologic Malignancies

Phase

Phase 3

Status

Active

Company

Bristol Myers Squibb

About Bristol Myers Squibb

Bristol Myers Squibb (BMS) is a premier global biopharmaceutical company with a mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. The company has achieved landmark status through transformative therapies like Opdivo (nivolumab) and Yervoy in immuno-oncology, and maintains a robust pipeline fueled by a strategy of causal human biology and modality matching. BMS's core strategy involves a disciplined R&D framework, strategic business development to bolster its pipeline, and a focus on expanding the reach of its cell therapy and novel oncology assets while navigating near-term patent expirations.

View full company profile

Therapeutic Areas

Oncology Hematology Cardiovascular Disease Immunology Neuroscience

Other Hematologic Malignancies Drugs

Drug	Company	Phase	Status
CER-T Cell Platform	CERo Therapeutics	Pre-clinical	Research & Development
Not Specified (Hematologic Malignancies)	AbelZeta Pharma	Clinical	Active
BGB-11417 (BCL-2 inhibitor)	BeiGene	Phase 2	Active
PredicineHEME™	Predicine	Commercial	Active
Trichostatin A (TSA)	Vanda Pharmaceuticals	Development	Active
DARIC-NK Program	Coeptis Therapeutics	Preclinical	Lead Optimization
TSC-102-A01	TScan Therapeutics	Preclinical	IND Cleared by FDA
TSC-102-A03	TScan Therapeutics	Preclinical	IND Cleared by FDA
LBL-007	LakeShore Biopharma	Phase 1/2	Active